Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 09:00 save search
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
Published: 2024-03-19 (Crawled : 09:00) - globenewswire.com
XRTX | $3.5 -3.05% -3.14% 12K
|
Mining, Quarrying, and Oil and ...
|
| O: 10.1%
H: 0.37%
C: -7.3%
trial
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: -0.56%
H: 0.0%
C: -0.38%
AKLI | $0.239 2.93% 2.85% 50K
|
|
| O: -3.85%
H: 12.67%
C: 6.92%
japan positive endeavorrx adhd trial results
Grifols announces positive topline phase 3 fibrinogen clinical trial results
Published: 2024-02-14 (Crawled : 09:00) - globenewswire.com
GRFS | News | $6.29 -3.82% -3.97% 1.2M
|
Health Technology
|
| O: 0.48%
H: 3.08%
C: 2.85%
positive topline trial results
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Published: 2024-01-24 (Crawled : 09:00) - prnewswire.com
SGMT | $4.0 0.76% 0.75% 430K
|
Health Technology
|
| O: 3.31%
H: 0.61%
C: -10.28%
asc40 first treatment trial acne
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Published: 2023-12-05 (Crawled : 09:00) - prnewswire.com
SGMT | $4.0 0.76% 0.75% 430K
|
Health Technology
|
| O: 0.99%
H: 7.07%
C: 1.22%
asc40 treatment trial acne
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Published: 2023-11-14 (Crawled : 09:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: 8.77%
H: 0.0%
C: 0.0%
lyt-300 trial
First results from PEGASUS trial reported at ESMO show promise for use of liquid biopsy to guide adjuvant treatment of colon cancer
Published: 2023-10-23 (Crawled : 09:00) - biospace.com/
GH M | $16.08 -3.54% -3.67% 1.9M
|
Health Services
|
| O: -0.51%
H: 5.33%
C: 1.88%
cancer treatment trial promise colon results show
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial
Published: 2023-09-22 (Crawled : 09:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.56%
H: 1.48%
C: 1.12%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 3.59%
H: 0.09%
C: -0.05%
ev-302 padcev bladder cancer trial
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Published: 2023-09-22 (Crawled : 09:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 2.01%
H: 0.2%
C: -0.79%
breast her2 cancer trial negative
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
Published: 2023-09-12 (Crawled : 09:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -1.67%
H: 2.31%
C: 1.22%
lung conference world presentation cancer trial results
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
Published: 2023-08-15 (Crawled : 09:00) - prnewswire.com
CALT | News | $17.65 -2.4% 4K
|
Health Technology
|
| O: -10.7%
H: 6.76%
C: 6.21%
lancet trial therapeutics results nefecon nefigard igan
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
Published: 2023-06-09 (Crawled : 09:00) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.4%
H: 4.46%
C: 3.37%
cell trial
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
Published: 2023-05-12 (Crawled : 09:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
rsv trial
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
Published: 2023-01-03 (Crawled : 09:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 5.68%
H: 8.13%
C: 4.87%
eslim-01 trial china
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
Published: 2022-12-23 (Crawled : 09:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.11%
H: 0.17%
C: -2.06%
bnt165 vaccine trial malaria phase 1
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Published: 2022-12-20 (Crawled : 09:00) - biospace.com/
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 24.54%
H: 19.82%
C: 10.65%
pharma trial
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Published: 2022-10-10 (Crawled : 09:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -0.6%
H: 7.53%
C: 1.46%
antibody anemia trial
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Sinovac Biotech Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Against 1Globe Capital LLC and Certain of its Officers - SVA
Published: 2022-09-07 (Crawled : 09:00) - prnewswire.com
TWTR | News | $53.7 0.3%
|
Technology Services
|
| O: 1.73%
H: 4.96%
C: 4.83%
biotech trial deadline
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2022-08-15 (Crawled : 09:00) - biospace.com/
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
enhertu treatment disease trial positive cancer her2- her2 metastatic breast cancer
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
Published: 2022-08-09 (Crawled : 09:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -0.22%
H: 0.0%
C: -1.73%
img-004 global trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.